Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half
Executive Summary
Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results
You may also be interested in...
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments
Wyeth will invest $60 mil. in Effexor manufacturing capacity expansion in 2003, CFO Kenneth Martin told the Credit Suisse First Boston investor conference Nov. 14 in Phoenix